autologous anti-CD19 (human derived) chimeric antigen receptor T cells
/ Beijing Boren Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 15, 2022
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
(clinicaltrials.gov)
- P2 | N=100 | Recruiting | Sponsor: Beijing Boren Hospital | Trial completion date: Nov 2022 ➔ Nov 2024 | Trial primary completion date: May 2022 ➔ May 2024
CAR T-Cell Therapy • IO biomarker • Preclinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • ABL1 • CD19
1 to 1
Of
1
Go to page
1